Coronavirus: age cap in Oxford vaccine trials casts doubt over results
AstraZeneca failed to disclose that under-55s made up test group in which jab was most effective

Oxford University and AstraZeneca are facing questions over their promising vaccine trial results after health officials revealed that key information about the ages of the test subjects was omitted.
During the Phase 3 trial, one group of test subjects was inoculated with two doses of the vaccine, spaced a month apart, while a second group was administered with a half-dose followed by a full one. In the first group, the protection rate was found to be 62%, but data from the second group showed that the vaccine was effective 90% of the time.
The reason for the wide discrepency has puzzled scientists. But they may now have their answer, after researcher Moncef Slaoui, who is spearheading the US’s vaccine distribution programme, told reporters that the age of participants in the second group “was capped at 55”, Bloomberg reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
No age breakdown was given in the reporting of the results, which have been cast into doubt over the omission of the most at-risk age demographics.
Former Pfizer research and development president Geoffrey Porges researchers “said he thought it was unlikely the AstraZeneca jab would get approval in the US after the company ‘tried to embellish their results’ by highlighting higher efficacy in a ‘relatively small subset of subjects in the study’”, the Financial Times reports.
Meanwhile, David Salisbury, an associate fellow of the global health programme at Chatham House, told The Telegraph: “You’ve taken two studies for which different doses were used and come up with a composite that doesn’t represent either of the doses. I think many people are having trouble with that.”
And the admission earlier this week by AstraZeneca that the half-dose was administered by error during the trials will add to “questions about whether the vaccine’s apparently spectacular efficacy will hold up under additional testing”, says The New York Times - which suggests that AstraZeneca’s “spotty disclosures have eroded confidence” in the jab.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Critics' choice: Three takes on tavern dining
Feature A second Minetta Tavern, A 1946 dining experience, and a menu with a mission
By The Week US
-
Film reviews: Warfare and A Minecraft Movie
Feature A combat film that puts us in the thick of it and five misfits fall into a cubic-world adventure
By The Week US
-
What to know before lending money to family or friends
the explainer Ensure both your relationship and your finances remain intact
By Becca Stanek, The Week US
-
The sneaking rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
By Theara Coleman, The Week US
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
By The Week US
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US